Stock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook

Stock Track

01-30

Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.

The key factors driving the stock's soar were:

1. Strong Q4 Revenue and Earnings Growth
Teva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher operating income.

2. Continued Momentum in 2025 Guidance
For 2025, Teva forecasts revenue of $16.8 billion to $17.4 billion, representing growth of 2% to 5% compared to 2024. The company expects its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, to maintain strong momentum, offsetting slower growth in its generics business. Teva's non-GAAP earnings per share guidance of $2.35 to $2.65 also exceeded analyst expectations.

3. Promising Pipeline and Strategic Focus
Teva highlighted its promising pipeline, including the potential of its anti-TL1A drug duvakitug for multiple indications, as well as its dual-action rescue inhaler and olanzapine LAI programs. The company also reaffirmed its strategic focus on driving growth through its innovative products, launching complex generics and biosimilars, and improving operational efficiency.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1147676754"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147676754\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1147676754?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-30 09:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147676754","market":"hk","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook","media":"Stock Track","content":"<html><body><p>Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.</p>\n<p>The key factors driving the stock's soar were:</p>\n<p>1. <b>Strong Q4 Revenue and Earnings Growth</b><br/>\nTeva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher operating income.</p>\n<p>2. <b>Continued Momentum in 2025 Guidance</b><br/>\nFor 2025, Teva forecasts revenue of $16.8 billion to $17.4 billion, representing growth of 2% to 5% compared to 2024. The company expects its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, to maintain strong momentum, offsetting slower growth in its generics business. Teva's non-GAAP earnings per share guidance of $2.35 to $2.65 also exceeded analyst expectations.</p>\n<p>3. <b>Promising Pipeline and Strategic Focus</b><br/>\nTeva highlighted its promising pipeline, including the potential of its anti-TL1A drug duvakitug for multiple indications, as well as its dual-action rescue inhaler and olanzapine LAI programs. The company also reaffirmed its strategic focus on driving growth through its innovative products, launching complex generics and biosimilars, and improving operational efficiency.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-01-30 09:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.</p>\n<p>The key factors driving the stock's soar were:</p>\n<p>1. <b>Strong Q4 Revenue and Earnings Growth</b><br/>\nTeva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher operating income.</p>\n<p>2. <b>Continued Momentum in 2025 Guidance</b><br/>\nFor 2025, Teva forecasts revenue of $16.8 billion to $17.4 billion, representing growth of 2% to 5% compared to 2024. The company expects its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, to maintain strong momentum, offsetting slower growth in its generics business. Teva's non-GAAP earnings per share guidance of $2.35 to $2.65 also exceeded analyst expectations.</p>\n<p>3. <b>Promising Pipeline and Strategic Focus</b><br/>\nTeva highlighted its promising pipeline, including the potential of its anti-TL1A drug duvakitug for multiple indications, as well as its dual-action rescue inhaler and olanzapine LAI programs. The company also reaffirmed its strategic focus on driving growth through its innovative products, launching complex generics and biosimilars, and improving operational efficiency.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦製藥","start_time":0,"source_url":"","article_id":"1147676754","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147676754","pubTimestamp":1738200531,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical Industries Ltd.  saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.Teva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher op","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"股票轨迹梯瓦制药(Teva Pharmaceutical)股价因强劲的第四季度业绩和乐观的2025年前景而飙升5.18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.\nThe key factors driving the stock's soar were:\n1. Strong Q4 Revenue and Earnings Growth\nTeva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher operating income.\n2. Continued Momentum in 2025 Guidance\nFor 2025, Teva forecasts revenue of $16.8 billion to $17.4 billion, representing growth of 2% to 5% compared to 2024. The company expects its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, to maintain strong momentum, offsetting slower growth in its generics business. Teva's non-GAAP earnings per share guidance of $2.35 to $2.65 also exceeded analyst expectations.\n3. Promising Pipeline and Strategic Focus\nTeva highlighted its promising pipeline, including the potential of its anti-TL1A drug duvakitug for multiple indications, as well as its dual-action rescue inhaler and olanzapine LAI programs. The company also reaffirmed its strategic focus on driving growth through its innovative products, launching complex generics and biosimilars, and improving operational efficiency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}